4925-300 E2 AccuBind ELISA Rev 4
4925-300 E2 AccuBind ELISA Rev 4
Number
Sample
Abs (A)
Abs (B)
(pg/ml)
Value
Mean
Well
time and temperature requirements prescribed are essential. 8. Goldstein D, et al, “Correlation between Estradiol and
I.D.
1.50 Table 1.
indicates excellent method agreement.
Reagent (fill)
C) 1 (6ml) 2 (6ml)
Patient TABLE 1
1.00 Expected Values for the Estradiol Test System
14.4 Specificity D) 1 plate 2 plates
Median Range The % cross reactivity of the estradiol antibody to selected
0.50
Females - - substances was evaluated by adding the interfering substance to a E) 1 (20ml) 1 (20ml)
Follicular Phase 48 9-175 serum matrix at various concentrations. The cross-reactivity was
0.00 F) 1 (12ml) 2 (12ml)
calculated by deriving a ratio between dose of interfering substance
Luteal Phase 103 44-196 to dose of estradiol needed to displace the same amount of labeled
0.00 0.50 1.00 1.50 2.00 2.50 3.00
G) 1 (8ml) 2 (8ml)
Periovulatory 209 107-281 analog.
Estradiol Value /1000 in pg/ml
Treated Menopausal 122 42-289
Untreated Menopausal 7.3 ND-20 Substance Cross
Note: Multiply the horizontal values by 1000 to convert into pg/ml. Reactivity
Oral Contraceptives 13 ND-103
Androstenedione 0.0003
Males 19 4-94 Dihydotestosterone 0.0008
11.0 Q.C. PARAMETERS
Cortisone <0.0001
During pregnancy the Estradiol serum levels rise rapidly till the end Corticosterone <0.0001
In order for the assay results to be considered valid the following
criteria should be met: of third trimester (17). Cortisol 0.0004
Estriol <0.0001
1. The absorbance (OD) of calibrator 0 pg/ml should be > 1.3.
It is important to keep in mind that establishment of a range of DHEA sulfate <0.0001
2. Four out of six quality control pools should be within the
values which can be expected to be found by a given method for a Estradiol <0.0001
established ranges.
population of "normal” persons is dependent upon a multiplicity of Estrone <0.0001
factors: the specificity of the method, the population tested and the Testosterone <0.0001
12.0 RISK ANALYSIS
precision of the method in the hands of the analyst. For these
reasons each laboratory should depend upon the range of expected
The MSDS and Risk Analysis Form for this product is available on
values established by the manufacturer only until an in-house range 15.0 REFERENCES
request from Monobind Inc.
can be determined by the analysts using the method with a
population indigenous to the area in which the laboratory is located. 1. Abraham GE. The application of natural steroid
12.1 Assay Performance
1. It is important that the time of reaction in each well is held radioimmunoassay to gynecologic endocrinology. In: Abraham
constant to achieve reproducible results. 14.0 PERFORMANCE CHARACTERISTICS GE, editor. Radioassay Systems in Clinical Endocrinology,
2. Pipetting of samples should not extend beyond ten (10) Basel: Marcel Dekker,: 475-529 (1981).
minutes to avoid assay drift. 14.1 Precision 2. Batzer F,”Hormonal evaluation of early pregnancy”, Fertility
3. Highly lipemic, hemolyzed or grossly contaminated The within and between assay precision of the estradiol AccuBind™ Sterility, 34:1-13 (1980).
specimen(s) should not be used. Microplate EIA Test System were determined by analyses on three 3. Bauman J, “Basal body temperature: unreliable method of
4. If more than one (1) plate is used, it is recommended to repeat different levels of pool control sera. The number, mean values, ovulation detection”, Fertility Sterility, 36:729-33, (1981).
the dose response curve. standard deviation and coefficient of variation for each of these 4. Bergquist C, Nillius SJ, Wide L “Human gonadotropin therapy:
5. The addition of substrate solution initiates a kinetic reaction, control sera are presented in Table 2 and Table 3. Serum estradiol and progesterone patterns during conceptual
which is terminated by the addition of the stop solution. cycles”, Fertility Sterility; 39:761-65 (1983).
Therefore, the substrate and stop solution should be added in TABLE 2 5. Gautray JP, et al, “Clinical investigation of the menstrual cycle:
the same sequence to eliminate any time-deviation during Within Assay Precision (Values in pg/ml) clinical, endometrial and endocrine aspects of luteal defects”,
Fertility Sterility, 35:296-303 (1981).
reaction. Sample N X σ C.V.
6. Hensleigh PA, Fainstat T, “Corpus luteum dysfunction: serum
6. Plate readers measure vertically. Do not touch the bottom of Low 20 81.9 8.1 9.9%
the wells. progesterone levels in diagnosis and assessment of therapy for
Normal 20 242.7 20.5 8.5% recurrent and threatened abortion”, Fertility Sterility, 32:396-9.
7. Failure to remove adhering solution adequately in the High 20 423.7 7.5 7.5%
aspiration or decantation wash step(s) may result in poor (1979)
replication and spurious results.